Franklin Street Advisors Inc. NC Purchases 11,668 Shares of Pfizer Inc. $PFE

Franklin Street Advisors Inc. NC boosted its position in Pfizer Inc. (NYSE:PFE) by 27.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,831 shares of the biopharmaceutical company’s stock after purchasing an additional 11,668 shares during the quarter. Franklin Street Advisors Inc. NC’s holdings in Pfizer were worth $1,329,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in PFE. Capital Advisory Group Advisory Services LLC increased its holdings in shares of Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after acquiring an additional 388 shares in the last quarter. Trust Co of the South increased its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after acquiring an additional 441 shares in the last quarter. Charter Oak Capital Management LLC increased its holdings in shares of Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock valued at $258,000 after acquiring an additional 444 shares in the last quarter. Ballentine Partners LLC increased its holdings in shares of Pfizer by 0.5% during the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company’s stock valued at $2,260,000 after acquiring an additional 458 shares in the last quarter. Finally, Members Trust Co increased its holdings in shares of Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 467 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PFE shares. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.41.

Pfizer Trading Up 1.1%

Shares of NYSE:PFE opened at $27.37 on Friday. The stock has a market capitalization of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock’s 50-day simple moving average is $24.67 and its two-hundred day simple moving average is $24.15. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.